Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. [electronic resource]
Producer: 20150512Description: 595-603 p. digitalISSN:- 1879-0852
- Adaptor Proteins, Signal Transducing
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Basic Helix-Loop-Helix Transcription Factors -- blood
- Biomarkers, Tumor -- blood
- Calcium-Binding Proteins
- Carcinoma, Renal Cell -- blood
- China
- Disease-Free Survival
- Female
- Humans
- Indazoles
- Indoles -- adverse effects
- Intercellular Signaling Peptides and Proteins -- blood
- Kaplan-Meier Estimate
- Kidney Neoplasms -- blood
- Logistic Models
- Male
- Middle Aged
- Multivariate Analysis
- Proportional Hazards Models
- Prospective Studies
- Pyrimidines -- adverse effects
- Pyrroles -- adverse effects
- Risk Factors
- Sulfonamides -- adverse effects
- Sunitinib
- Time Factors
- Treatment Failure
- Vascular Endothelial Growth Factor A -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.